Sarepta Therapeutics EBITDA 2010-2024 | SRPT

Sarepta Therapeutics EBITDA for the quarter ending June 30, 2024 was $-0.002B, a 98.18% decline year-over-year.

  • Sarepta Therapeutics 2023 EBITDA was -0.27B, a 46.61% decline from 2022.
  • Sarepta Therapeutics 2022 EBITDA was -0.505B, a 19.72% increase from 2021.
  • Sarepta Therapeutics 2021 EBITDA was -0.422B, a 21.49% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Sarepta Therapeutics EBITDA 2010-2024 | SRPT

  • Sarepta Therapeutics 2023 EBITDA was -0.27B, a 46.61% decline from 2022.
  • Sarepta Therapeutics 2022 EBITDA was -0.505B, a 19.72% increase from 2021.
  • Sarepta Therapeutics 2021 EBITDA was -0.422B, a 21.49% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.